Major achievements of evidence-based traditional Chinese medicine in treating major diseases

Biochemical Pharmacology

Volumn 139, Issue , 2017, Pages 94-104

  Chao, Jung ^a,b,c   Dai, Yuntao ^a   Verpoorte, Robert ^d   Lam, Wing ^e   Cheng, Yung Chi ^e   Pao, Li Heng ^b   Zhang, Wei ^a   Chen, Shilin ^a  

^a INSTITUTE OF CHINESE MATERIA MEDICA   (China)

^b CHANG GUNG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Taiwan)

^c CHINA MEDICAL UNIVERSITY   (Taiwan)

^d LEIDEN UNIVERSITY   (Netherlands)

^e YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Artemisinin; Drug development; Evidence based traditional medicines; Quality control; Traditional Chinese medicine; Western medicine

Indexed keywords

ARSENIC TRIOXIDE; ARTEMISININ; BANLANGEN; BERBERINE; CHINESE DRUG; CROFELEMER; DANHONG INJECTION; DANTONIC; DI AO XINXUEKANG CAPSULE; FUZHENG HUAYU TABLET; GANODERMA LUCIDUM EXTRACT; GEGEN QINLIAN DECOCTION; GUIZHI FULING CAPSULE; HMPL 004; HUANGQIN TANG; KANGLAITE INJECTION; LIANHUA QINGWEN CAPSULE; LIU JUN ZI TANG; MAXINGSHGAN YINQIAOSAN; QILI QIANGXIN CAPSULE; REALGAR INDIGO NATURALIS; SALVIA MILTIORRHIZA EXTRACT; SHENFU INJECTION; SINECATECHINS; TETRANDRINE; UNCLASSIFIED DRUG; XUEZHIKANG; XUEZHIKANG CAPSULE; HERBACEOUS AGENT; NEW DRUG; PLANT MEDICINAL PRODUCT;

ACUTE HEART INFARCTION; ANGINA PECTORIS; BACTERIAL DIARRHEA; BRAIN ISCHEMIA; CARDIOVASCULAR DISEASE; CHINESE MEDICINE; CHRONIC HEPATITIS C; CONDYLOMA ACUMINATUM; DIARRHEA; DYSMENORRHEA; EBOLA HEMORRHAGIC FEVER; EVIDENCE BASED MEDICINE; GASTROINTESTINAL DISEASE; HEART FAILURE; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; INFLAMMATORY BOWEL DISEASE; INFLUENZA A (H1N1); LIVER FIBROSIS; MALARIA; MALIGNANT NEOPLASM; MEDICAL PRACTICE; NON SMALL CELL LUNG CANCER; PANCREAS CANCER; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; QUALITY CONTROL; RECTUM CANCER; REVIEW; SEASONAL INFLUENZA; STABLE ANGINA PECTORIS; ULCERATIVE COLITIS; WESTERN MEDICINE; ANIMAL; CHEMISTRY; CHINA; CHRONIC DISEASE; COMPARATIVE STUDY; DRUG DESIGN; DRUG DEVELOPMENT; HEALTH CARE QUALITY; ISOLATION AND PURIFICATION; STANDARDS; TOTAL QUALITY MANAGEMENT; TRANSLATIONAL RESEARCH; TRENDS; WESTERN WORLD;

ANIMALS; CHINA; CHRONIC DISEASE; DRUG DESIGN; DRUG DISCOVERY; DRUGS, CHINESE HERBAL; DRUGS, INVESTIGATIONAL; EVIDENCE-BASED MEDICINE; HUMANS; MEDICINE, CHINESE TRADITIONAL; PHYTOCHEMICALS; QUALITY ASSURANCE, HEALTH CARE; QUALITY CONTROL; QUALITY IMPROVEMENT; QUALITY OF HEALTH CARE; TRANSLATIONAL MEDICAL RESEARCH; WESTERN WORLD;

EID: 85021386786     PISSN: 00062952     EISSN: 18732968     Source Type: Journal    
DOI: 10.1016/j.bcp.2017.06.123     Document Type: Review

References (106)

1. Newman, D.J., Cragg, G.M., Natural Products as Sources of New Drugs from 1981 to 2014. J. Nat. Prod. 79:3 (2016), 629–661.
2. Newman, D.J., Cragg, G.M., Natural products as sources of new drugs over the 30 years from 1981 to 2010. J. Nat. Prod. 75:3 (2012), 311–335.
3. Newman, D.J., Cragg, G.M., Natural products as sources of new drugs over the last 25 years. J. Nat. Prod. 70:3 (2007), 461–477.
4. Newman, D.J., Cragg, G.M., Snader, K.M., Natural products as sources of new drugs over the period 1981–2002. J. Nat. Prod. 66:7 (2003), 1022–1037.
5. Schroën, Yan, van Wietmarschen, Herman A., Wang, Mei, van Wijk, Eduard P., Hankemeier, Thomas, Guowang, Xu., et al. East is East and West is West, and never the twain shall meet?. Science 346:6216 Suppl (2015), S10–S12.
6. Verpoorte, R., Choi, Y.H., Kim, H.K., Ethnopharmacology and systems biology: a perfect holistic match. J. Ethnopharmacol. 100:1–2 (2005), 53–56.
7. Chao, J., Lu, T.C., Liao, J.W., Huang, T.H., Lee, M.S., Cheng, H.Y., et al. Analgesic and anti-inflammatory activities of ethanol root extract of Mahonia oiwakensis in mice. J. Ethnopharmacol. 125:2 (2009), 297–303.
8. Briggs, J.P., A global scientific challenge: Learning the right lessons from ancient healing practices. Science 346:6216 Suppl (2015), S7–S9.
9. Harvey, A.L., Edrada-Ebel, R., Quinn, R.J., The re-emergence of natural products for drug discovery in the genomics era. Nat. Rev. Drug Discovery 14:2 (2015), 111–129.
10. Rafii, M.S., Walsh, S., Little, J.T., Behan, K., Reynolds, B., Ward, C., et al. Alzheimer's Disease Cooperative A phase II trial of huperzine A in mild to moderate Alzheimer disease. Neurology 76:16 (2011), 1389–1394.
11. Stermitz, F.R., Lorenz, P., Tawara, J.N., Zenewicz, L.A., Lewis, K., Synergy in a medicinal plant: antimicrobial action of berberine potentiated by 5’-methoxyhydnocarpin, a multidrug pump inhibitor. Proc. Natl. Acad. Sci. U.S.A. 97:4 (2000), 1433–1437.
12. Abreu, A.C., Coqueiro, A., Sultan, A., Lemmens, N., Kim, H.K., Verpoorte, R., et al. Looking to nature for a new concept in antimicrobial treatments: isoflavonoids from Cytisus striatus as antibiotic adjuvants against MRSA. Sci. Rep., 2017.
13. Friedemann, Thomas, Li, Min, Fei, Jian, Schumacher, Udo, Song, Juxian, Schröder, S., Hypothesis-driven screening of Chinese herbs for compounds that promote neuroprotection. Science 350:6262 (2015), S69–S71.
14. Medina-Franco, J.L., Giulianotti, M.A., Welmaker, G.S., Houghten, R.A., Shifting from the single to the multitarget paradigm in drug discovery. Drug Discovery Today 18:9–10 (2013), 495–501.
15. Tu, Y., The discovery of artemisinin (qinghaosu) and gifts from Chinese medicine. Nat. Med. 17:10 (2011), 1217–1220.
16. Verpoorte, R., Good practices: the basis for evidence-based medicines. J. Ethnopharmacol. 140:3 (2012), 455–457.
17. Wei Jia, Tai-ping Fan, Xiaoning Wang, G. Xie, The polypharmacokinetics of herbal medicines., Science 350(6262) (2015) S76–S79.
18. Wang, M., Lamers, R.J., Korthout, H.A., van Nesselrooij, J.H., Witkamp, R.F., van der Heijden, R., et al. Metabolomics in the context of systems biology: bridging traditional Chinese medicine and molecular pharmacology. Phytother. Res: PTR 19:3 (2005), 173–182.
19. Swinney, D.C., Anthony, J., How were new medicines discovered?. Nat. Rev. Drug Discovery 10:7 (2011), 507–519.
20. Moffat, J.G., Rudolph, J., Bailey, D., Phenotypic screening in cancer drug discovery – past, present and future. Nat. Rev. Drug Discovery 13:8 (2014), 588–602.
21. Han, J., Lee, J.G., Min, S.S., Park, S.H., Angerhofer, C.K., Cordell, G.A., et al. Synthesis of new artemisinin analogues from artemisinic acid modified at C-3 and C-13 and their antimalarial activity. J. Nat. Prod. 64:9 (2001), 1201–1205.
22. Klayman, D.L., Lin, A.J., Acton, N., Scovill, J.P., Hoch, J.M., Milhous, W.K., et al. Isolation of artemisinin (qinghaosu) from Artemisia annua growing in the United States. J. Nat. Prod. 47:4 (1984), 715–717.
23. Misra, L.N., Ahmad, A., Thakur, R.S., Lotter, H., Wagner, H., Crystal structure of artemisinic acid: a possible biogenetic precursor of antimalarial artemisinin from Artemisia annua. J. Nat. Prod. 56:2 (1993), 215–219.
24. Ranasinghe, A., Sweatlock, J.D., Cooks, R.G., A rapid screening method for artemisinin and its congeners using ms/ms: search for new analogues in Artemisia annua. J. Nat. Prod. 56:4 (1993), 552–563.
25. Wallaart, T.E., van Uden, W., Lubberink, H.G., Woerdenbag, H.J., Pras, N., Quax, W.J., Isolation and identification of dihydroartemisinic acid from Artemisia annua and its possible role in the biosynthesis of artemisinin. J. Nat. Prod. 62:3 (1999), 430–433.
26. Zi-Feng Yang, Elaine Lai-Han Leung, Liang Liu, Zhi-Hong Jiang, N. Zhong, Developing influenza treatments using traditional Chinese medicine, Science 347(6219 Suppl) (2015) S35–S37.
27. L. Jiang, L. Deng, T. Wu, Chinese medicinal herbs for influenza, The Cochrane database of systematic reviews (3) (2013) CD004559.
28. Tu, Y., Artemisinin-a gift from traditional chinese medicine to the world (Nobel Lecture). Angew. Chem. 55:35 (2016), 10210–10226.
29. Ho, W.E., Peh, H.Y., Chan, T.K., Wong, W.S., Artemisinins: pharmacological actions beyond anti-malarial. Pharmacol. Ther. 142:1 (2014), 126–139.
30. Tao, Z., Yang, Y., Shi, W., Xue, M., Yang, W., Song, Z., et al. Complementary and alternative medicine is expected to make greater contribution in controlling the prevalence of influenza. Biosci. Trends 7:5 (2013), 253–256.
31. Dong, L., Xia, J.W., Gong, Y., Chen, Z., Yang, H.H., Zhang, J., et al. Effect of lianhuaqingwen capsules on airway inflammation in patients with acute exacerbation of chronic obstructive pulmonary disease. Evidence-based complementary and alternative medicine: eCAM, 2014, 2014, 637969.
32. Zhao, P., Yang, H.Z., Lv, H.Y., Wei, Z.M., Efficacy of Lianhuaqingwen capsule compared with oseltamivir for influenza A virus infection: a meta-analysis of randomized, controlled trials. Altern. Ther. Health Med. 20:2 (2014), 25–30.
33. Duan, Z.P., Jia, Z.H., Zhang, J., Liu, S., Chen, Y., Liang, L.C., et al. Natural herbal medicine Lianhuaqingwen capsule anti-influenza A (H1N1) trial: a randomized, double blind, positive controlled clinical trial. Chin. Med. J. 124:18 (2011), 2925–2933.
34. Wang, C., Cao, B., Liu, Q.Q., Zou, Z.Q., Liang, Z.A., Gu, L., et al. Oseltamivir compared with the Chinese traditional therapy maxingshigan-yinqiaosan in the treatment of H1N1 influenza: a randomized trial. Ann. Internal Med. 155:4 (2011), 217–225.
35. Yang, Z., Wang, Y., Zheng, Z., Zhao, S., Zhao, J., Q. L et al., Antiviral activity of Isatis indigotica root-derived clemastanin B against human and avian influenza A and B viruses in vitro. Int. J. Mol. Med. 31:4 (2013), 867–873.
36. Mok, C.K., Kang, S.S., Chan, R.W., Yue, P.Y., Mak, N.K., Poon, L.L., et al. Anti-inflammatory and antiviral effects of indirubin derivatives in influenza A (H5N1) virus infected primary human peripheral blood-derived macrophages and alveolar epithelial cells. Antiviral Res. 106 (2014), 95–104.
37. Mak, N.K., Leung, C.Y., Wei, X.Y., Shen, X.L., Wong, R.N., Leung, K.N., et al. Inhibition of RANTES expression by indirubin in influenza virus-infected human bronchial epithelial cells. Biochem. Pharmacol. 67:1 (2004), 167–174.
38. Lai, G.H., Chao, J., Lin, M.K., Chang, W.T., Peng, W.H., Sun, F.C., et al. Rapid and sensitive identification of the herbal tea ingredient Taraxacum formosanum using loop-mediated isothermal amplification. Int. J. Mol. Sci. 16:1 (2015), 1562–1575.
39. Chen, Shilin, Song, Jingyuan, Sun, Chao, Jiang, Xu., Zhu, Yingjie, Verpoorte, Rob, et al. Herbal genomics: examining the biology of traditional medicines. Science 347:6219 Suppl (2015), S27–S29.
40. Chao, J., Dai, Y., Cheng, H.Y., Lam, W., Cheng, Y.C., Li, K., et al. Improving the Concentrations of the Active Components in the Herbal Tea Ingredient Uraria crinita: The Effect of Post-harvest Oven-drying Processing. Sci. Rep., 7, 2017, 38763.
41. Yao, S., Zhang, J., Wang, D., Hou, J., Yang, W., Da, J., et al. Discriminatory components retracing strategy for monitoring the preparation procedure of Chinese patent medicines by fingerprint and chemometric analysis. PloS One, 10(3), 2015, e0121366.
42. Approved Labeling for Veregen (NDA 021902), http://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021902s000_prntlbl.pdf.
43. Drug Approval Package, Drugs@FDA FDA: Veregen (NDA 021902), http://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021902s000TOC.cfm.
44. Approved Labeling for Fulyzaq (NDA 202292) http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202292Orig1s000Lbl.pdf.
45. Drug Approval Package, Drugs@FDA FDA: Fulyzaq Delayed-Release Tablets (NDA 202292) http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202292Orig1s000TOC.cfm.
46. Lee, Sau L., Dou, Jinhui, Agarwal, Rajiv, Temple, Robert, Beitz, Julie, Wu, Charles, et al. Evolution of traditional medicines to botanical drugs. Science 347:6219 Suppl (2015), S32–S34.
47. Chen, S., Pang, X., Song, J., Shi, L., Yao, H., Han, J., et al. A renaissance in herbal medicine identification: from morphology to DNA. Biotechnol. Adv. 32:7 (2014), 1237–1244.
48. Chen, S.L., Song, J.Y., Herbgenomics. China J. Chin. Mater. Med. 41 (2016), 3881–3889.
49. Botanical Drug Development Guidance for Industry, http://www.fda.gov/downloads/AboutFDA/CentersOffices/CDER/ucm106136.pdf, 2016.
50. Chang, J., Medicinal herbs: drugs or dietary supplements?. Biochem. Pharmacol. 59:3 (2000), 211–219.
51. Chen, S., Xu, J., Liu, C., Zhu, Y., Nelson, D.R., Zhou, S., et al. Genome sequence of the model medicinal mushroom Ganoderma lucidum. Nat. Commun., 3, 2012, 913.
52. Sakurai, Y., Kolokoltsov, A.A., Chen, C.C., Tidwell, M.W., Bauta, W.E., Klugbauer, N., et al. Two-pore channels control Ebola virus host cell entry and are drug targets for disease treatment. Science 347:6225 (2015), 995–998.
53. Yu, Y., Hu, S., Li, G., Xue, J., Li, Z., Liu, X., et al. Comparative effectiveness of Di'ao Xin Xue Kang capsule and Compound Danshen tablet in patients with symptomatic chronic stable angina. Sci. Rep., 4, 2014, 7058.
54. Jia, Y., Chen, C., Ng, C.S., Leung, S.W., Meta-analysis of randomized controlled trials on the efficacy of Di'ao xinxuekang capsule and isosorbide dinitrate in treating angina pectoris. Evidence-based complementary and alternative medicine: eCAM, 2012, 2012, 904147.
55. Wang, L.Y., Tang, J.Y., Liu, J., Lu, W., Yu, Y.N., Chen, B.W., et al. Dynamic changes in phenotypic groups in patients with stable angina pectoris after treatment with xinxuekang capsule: a randomized controlled trial. Curr. Vasc. Pharmacol. 13:4 (2015), 492–503.
56. Sun, J., Zhang, K., Xiong, W.J., Yang, G.Y., Zhang, Y.J., Wang, C.C., et al. Clinical effects of a standardized Chinese herbal remedy Qili Qiangxin, as an adjuvant treatment in heart failure: systematic review and meta-analysis. BMC Complementary Altern. Med., 16, 2016, 201.
57. Tang, W.H., Huang, Y., Cardiotonic modulation in heart failure: insights from traditional Chinese medicine. J. Am. Coll. Cardiol. 62:12 (2013), 1073–1074.
58. Li, X., Zhang, J., Huang, J., Ma, A., Yang, J., Li, W., Efficacy, G., Safety of Qili Qiangxin Capsules for Chronic Heart Failure Study. A multicenter, randomized, double-blind, parallel-group, placebo-controlled study of the effects of qili qiangxin capsules in patients with chronic heart failure. J. Am. College Cardiol. 62:12 (2013), 1065–1072.
59. Liao, P., Wang, L., Guo, L., Zeng, R., Huang, J., Zhang, M., Danhong injection (a traditional chinese patent medicine) for acute myocardial infarction: a systematic review and meta-analysis. Evidence-based complementary and alternative medicine: eCAM, 2015, 2015, 646530.
60. Wang, P.Q., Li, D.D., Dong, W., Liu, J., Yu, Y.N., Shen, C.T., et al. Danhong injection in the treatment of chronic stable angina: study protocol for a randomized controlled trial. Trials, 16, 2015, 474.
61. Li, B., Wang, Y., Lu, J., Liu, J., Yuan, Y., Yu, Y., et al. Evaluating the effects of Danhong injection in treatment of acute ischemic stroke: study protocol for a multicenter randomized controlled trial. Trials, 16, 2015, 561.
62. Zhang, X., Wang, H., Chang, Y., Wang, Y., Lei, X., Fu, S., et al. An overview of meta-analyses of danhong injection for unstable angina. Evidence-based complementary and alternative medicine: eCAM, 2015, 2015, 358028.
63. Wang, H., Ren, S., Liu, C., Zhang, X., An overview of systematic reviews of danhong injection for ischemic stroke. Evidence-based complementary and alternative medicine: eCAM, 2016, 2016, 8949835.
64. Zhang, N., Liu, J., Qiu, Z., Ye, Y., Zhang, J., Lou, T., Shenfu injection for improving cellular immunity and clinical outcome in patients with sepsis or septic shock. Am. J. Emergency Med., 2016.
65. Wen-Ting, S., Fa-Feng, C., Li, X., Cheng-Ren, L., Jian-Xun, L., Chinese medicine shenfu injection for heart failure: a systematic review and meta-analysis. Evidence-based complementary and alternative medicine: eCAM, 2012, 2012, 713149.
66. Liu, C., Hou, Y., Wang, X., Zhao, Z., Liu, Z., Zhai, J., Mao, J., Shang, H., Clinical assessment of Shenfu injection loading in the treatment of patients with exacerbation of chronic heart failure due to coronary heart disease: study protocol for a randomized controlled trial. Trials, 16, 2015, 222.
67. Li, M., He, Q., Chen, Y., Li, B., Feng, B., Zhang, Z., Wang, J., Xuezhikang capsule for type 2 diabetes with hyperlipemia: a systematic review and meta-analysis of randomized clinical trails. Evidence-based complementary and alternative medicine: eCAM, 2015, 2015, 468520.
68. Moriarty, P.M., Roth, E.M., Karns, A., Ye, P., Zhao, S.P., Liao, Y., et al. Effects of Xuezhikang in patients with dyslipidemia: a multicenter, randomized, placebo-controlled study. J. Clin. Lipidol. 8:6 (2014), 568–575.
69. Feng, Y., Xu, H., Chen, K., Natural polypill Xuezhikang: its clinical benefit and potential multicomponent synergistic mechanisms of action in cardiovascular disease and other chronic conditions. J. Altern. Complementary Med. 18:4 (2012), 318–328.
70. Ye, P., Lu, Z.L., Du, B.M., Chen, Z., Wu, Y.F., Yu, X.H., et al. Investigators Effect of xuezhikang on cardiovascular events and mortality in elderly patients with a history of myocardial infarction: a subgroup analysis of elderly subjects from the China Coronary Secondary Prevention Study. J. Am. Geriatrics Soc. 55:7 (2007), 1015–1022.
71. Li, J.J., Lu, Z.L., Kou, W.R., Chen, Z., Wu, Y.F., Yu, X.H., et al. Chinese coronary secondary prevention study, impact of xuezhikang on coronary events in hypertensive patients with previous myocardial infarction from the china coronary secondary prevention study (CCSPS). Ann. Med. 42:3 (2010), 231–240.
72. Li, J.J., Lu, Z.L., Kou, W.R., Chen, Z., Wu, Y.F., Yu, X.H., et al. Chinese coronary secondary prevention study, beneficial impact of xuezhikang on cardiovascular events and mortality in elderly hypertensive patients with previous myocardial infarction from the china coronary secondary prevention study (CCSPS). J. Clin. Pharmacol. 49:8 (2009), 947–956.
73. Yu, H.H., Kim, K.J., Cha, J.D., Kim, H.K., Lee, Y.E., Choi, N.Y., et al. Antimicrobial activity of berberine alone and in combination with ampicillin or oxacillin against methicillin-resistant Staphylococcus aureus. J. Med. Food 8:4 (2005), 454–461.
74. Dong, H., Wang, N., Zhao, L., Lu, F., Berberine in the treatment of type 2 diabetes mellitus: a systemic review and meta-analysis. Evid Based Complement Alternat. Med., 2012, 2012, 591654.
75. Kong, W., Wei, J., Abidi, P., Lin, M., Inaba, S., Li, C., et al. Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins. Nat. Med. 10:12 (2004), 1344–1351.
76. Xu, J., Lian, F., Zhao, L., Zhao, Y., Chen, X., Zhang, X., et al. Structural modulation of gut microbiota during alleviation of type 2 diabetes with a Chinese herbal formula. ISME J 9:3 (2015), 552–562.
77. Zhang, C.H., Xu, G.L., Liu, Y.H., Rao, Y., Yu, R.Y., Zhang, Z.W., et al. Anti-diabetic activities of Gegen Qinlian Decoction in high-fat diet combined with streptozotocin-induced diabetic rats and in 3T3-L1 adipocytes. Phytomedicine 20:3–4 (2013), 221–229.
78. Tong, X.L., Zhao, L.H., Lian, F.M., Zhou, Q., Xia, L., Zhang, J.C., et al. Clinical observations on the dose-effect relationship of gegen qin lian decoction on 54 out-patients with type 2 diabetes. J. Tradit Chin. Med. 31:1 (2011), 56–59.
79. Zhang, X.W., Yan, X.J., Zhou, Z.R., Yang, F.F., Wu, Z.Y., Sun, H.B., et al. Arsenic trioxide controls the fate of the PML-RARalpha oncoprotein by directly binding PML. Science 328:5975 (2010), 240–243.
80. Hu, J., Liu, Y.F., Wu, C.F., Xu, F., Shen, Z.X., Zhu, Y.M., et al. Long-term efficacy and safety of all-trans retinoic acid/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia. Proc. Natl. Acad. Sci. U.S.A. 106:9 (2009), 3342–3347.
81. Zheng, P.Z., Wang, K.K., Zhang, Q.Y., Huang, Q.H., Du, Y.Z., Zhang, Q.H., et al. Systems analysis of transcriptome and proteome in retinoic acid/arsenic trioxide-induced cell differentiation/apoptosis of promyelocytic leukemia. Proc. Natl. Acad. Sci. U.S.A. 102:21 (2005), 7653–7658.
82. Wang, L., Zhou, G.B., Liu, P., Song, J.H., Liang, Y., Yan, X.J., et al. Dissection of mechanisms of Chinese medicinal formula Realgar-Indigo naturalis as an effective treatment for promyelocytic leukemia. Proc. Natl. Acad. Sci. U.S.A. 105:12 (2008), 4826–4831.
83. Chang, C.J., Lin, C.S., Lu, C.C., Martel, J., Ko, Y.F., Ojcius, D.M., et al. Ganoderma lucidum reduces obesity in mice by modulating the composition of the gut microbiota. Nat. Commun., 6, 2015, 7489.
84. Bishop, K.S., Kao, C.H., Xu, Y., Glucina, M.P., Paterson, R.R., Ferguson, L.R., From 2000years of Ganoderma lucidum to recent developments in nutraceuticals. Phytochemistry 114 (2015), 56–65.
85. Jin, X., Ruiz Beguerie, J., Sze, D.M., Chan, G.C., Ganoderma lucidum (Reishi mushroom) for cancer treatment. Cochrane Database Syst. Rev., 4, 2016, CD007731.
86. Tominaga, K., Arakawa, T., Clinical application of kampo medicine (rikkunshito) for common and/or intractable symptoms of the gastrointestinal tract. Front. Pharmacol., 6, 2015, 7.
87. Fujitsuka, N., Asakawa, A., Morinaga, A., Amitani, M.S., Amitani, H., Katsuura, G., et al. Increased ghrelin signaling prolongs survival in mouse models of human aging through activation of sirtuin1. Mol. Psychiatry 21:11 (2016), 1613–1623.
88. Zhou, R., Luo, F., Lei, H., Zhang, K., Liu, J., He, H., et al. Liujunzi Tang, a famous traditional Chinese medicine, ameliorates cigarette smoke-induced mouse model of COPD. J. Ethnopharmacol. 193 (2016), 643–651.
89. Fujitsuka, N., Uezono, Y., Rikkunshito, a ghrelin potentiator, ameliorates anorexia-cachexia syndrome. Front. Pharmacol., 5, 2014, 271.
90. Takeda, H., Sadakane, C., Hattori, T., Katsurada, T., Ohkawara, T., Nagai, K., et al. Rikkunshito, an herbal medicine, suppresses cisplatin-induced anorexia in rats via 5-HT2 receptor antagonism. Gastroenterology 134:7 (2008), 2004–2013.
91. Jia, Y., Huang, F., Zhang, S., Leung, S.W., Is danshen (Salvia miltiorrhiza) dripping pill more effective than isosorbide dinitrate in treating angina pectoris? A systematic review of randomized controlled trials. Int. J. Cardiol. 157:3 (2012), 330–340.
92. Yao, Y., Feng, Y., Lin, W., Systematic review and meta-analysis of randomized controlled trials comparing compound danshen dripping pills and isosorbide dinitrate in treating angina pectoris. Int. J. Cardiol. 182 (2015), 46–47.
93. Ling, S., Luo, R.Z., Nheu, L., Guo, Z.X., Sun, H., Komesaroff, P.A., A phase I dose-escalation study to evaluate tolerability in a Western population to T89, a modern cardiovascular herbal medicine. J. Cardiovasc. Pharmacol. 60:6 (2012), 513–519.
94. Lu, Y., Li, C.S., Dong, Q., Chinese herb related molecules of cancer-cell-apoptosis: a minireview of progress between Kanglaite injection and related genes. J. Exp. Clin. Cancer Res.: CR, 27, 2008, 31.
95. Michelsen, K.S., Wong, M.H., Ko, B., Thomas, L.S., Dhall, D., Targan, S.R., HMPL-004 (Andrographis paniculata extract) prevents development of murine colitis by inhibiting T-cell proliferation and TH1/TH17 responses. Inflammatory Bowel Diseases 19:1 (2013), 151–164.
96. Sandborn, W.J., Targan, S.R., Byers, V.S., Rutty, D.A., Mu, H., Zhang, X., et al. Andrographis paniculata extract (HMPL-004) for active ulcerative colitis. Am. J. Gastroenterol. 108:1 (2013), 90–98.
97. Tang, T., Targan, S.R., Li, Z.S., Xu, C., Byers, V.S., Sandborn, W.J., Randomised clinical trial: herbal extract HMPL-004 in active ulcerative colitis – a double-blind comparison with sustained release mesalazine. Alimentary Pharmacol. Ther. 33:2 (2011), 194–202.
98. Liu, S.H., Cheng, Y.C., Old formula, new Rx: the journey of PHY906 as cancer adjuvant therapy. J. Ethnopharmacol. 140:3 (2012), 614–623.
99. Lam, W., Bussom, S., Guan, F., Jiang, Z., Zhang, W., Gullen, E.A., et al. The four-herb Chinese medicine PHY906 reduces chemotherapy-induced gastrointestinal toxicity. Sci. Transl. Med., 2(45), 2010, 45ra59.
100. Lam, Wing, Liu, Shwu-Huey, Jiang, Z., Cheng, Y.-C., Lessons from the development of the traditional Chinese medicine formula PHY906. Science 347:6219 Suppl (2015), S43–S44.
101. Dong, S., Chen, Q.L., Su, S.B., Curative effects of fuzheng huayu on liver fibrosis and cirrhosis: a meta-analysis. Evidence-based complementary and alternative medicine: eCAM, 2015, 2015, 125659.
102. Liu, P., Fuzheng huayu capsule in the treatment of liver fibrosis: clinical evidence and mechanism of action. Chin. J. Integr. Med. 18:5 (2012), 398–400.
103. Liu, C., Hu, Y., Xu, L., Liu, C., Liu, P., Effect of Fuzheng Huayu formula and its actions against liver fibrosis. Chin. Med., 4, 2009, 12.
104. Zhong, Y.X., Jin, X.L., Gu, S.Y., Peng, Y., Zhang, K.R., Ou-Yang, B.C., et al. Integrated identification, qualification and quantification strategy for pharmacokinetic profile study of Guizhi Fuling capsule in healthy volunteers. Sci. Rep., 6, 2016, 31364.
105. Lee, J.A., Park, S., Jung, J., Jun, J.H., Choi, J., Lee, M.S., Herbal medicine (Gyejibongneyong-hwan) for treating primary dysmenorrhoea: a protocol for a systematic review of randomised controlled trials. BMJ Open, 6(9), 2016, e011071.
106. Chen, N.N., Han, M., Yang, H., Yang, G.Y., Wang, Y.Y., Wu, X.K., et al. Chinese herbal medicine Guizhi Fuling Formula for treatment of uterine fibroids: a systematic review of randomised clinical trials. BMC Complementary Altern. Med., 14, 2014, 2.